CLAIMS

1. A compound having formula I or a pharmaceutically acceptable salt or hydrate thereof:



(I),

wherein:

ring A is an optionally substituted ring selected from phenyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and thiazolyl, wherein the substituents when present, are independently selected from chloro, fluoro, $-CF_3$, $-CHF_2$, $-CH_3$, $-CH_2CH_3$, $-CF_2CH_3$, -OH, $-OCH_3$, $-OCH_2CH_3$, $-NH_2$, $-NH(CH_3)$, and $-N(CH_3)_2$;

ring B is an optionally substituted 5-6 member monocyclic aryl or monocyclic heteroaryl, wherein the substituents when present, are independently selected from halo; -CN; -OH; C_1-C_4 alkyl optionally substituted with halo, CN or -OH; $-S(O)_2$-C_1-C_4 alkyl; -S(O)-C_1-C_4 alkyl; $-S(O)_2$-NH-C_1-C_4 alkyl; $-S(O)_2$-$N(C_1$-C_4 alkyl$)_2$; $-S(O)_2$-azetidin-1-yl; -O-C_1-C_4 alkyl; $-CH_2$-O-CH_3, morpholin-4-yl, cyclopropyl, $-S(O)_2$-NH-cyclopropyl, and -C(O)-O-CH_3;

R^1 and R^3 are each independently selected from hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl, -O-C_1-C_4 alkyl, and CN, wherein any alkyl portion of R^1 is optionally substituted with -OH, NH_2, $NH(C_1$-C_4 alkyl), or $N(C_1$-C_4 alkyl$)_2$;

R^2 is selected from: -(C_1-C_6 alkyl), -(C_2-C_6 alkenyl or alkynyl), -(C_1-C_6 alkylene)-$N(R^6)$-(C_1-C_6 alkylene)-O-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-$N(R^6)$-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-$N(R^6)(R^6)$, -(C_1-C_6 alkylene)-$N(R^6)$-$S(O)_{1-2}$-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-$N(R^6)$-$S(O)_{1-2}$-(C_0-C_6 alkyl)-Q, -(C_1-C_6 alkylene)-$S(O)_{1-2}$-$N(R^6)(R^6)$, -(C_1-C_4

alkylene)-$S(O)_{1-2}$-$N(R^6)$-(C_1-C_6 alkylene)-Q, -$C(O)N(R^6)$-(C_1-C_6 alkylene)-C(O)- (C_0-C_6 alkylene)-O-(C_1-C_6 alkyl), -$C(O)N(R^6)$-(C_1-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-O-C(O)-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-O-C(O)-(C_0-C_6 alkyl)-Q, -(C_1-C_6 alkylene)-O-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-O-(C_1-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_1-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-O-C(O)-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-O-C(O)-(C_0-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-C(O)$N(R^6)$-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-C(O)$N(R^6)$-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-$N(R^6)$C(O)-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-$N(R^6)$C(O)-(C_0-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-$S(O)_{0-2}$-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-$S(O)_{0-2}$-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-$N(R^6)$-C(O)-$N(R^6)$-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-C(O)-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-Q,

wherein:

any alkyl or alkylene moiety present in R^2 is optionally substituted with one or more -OH, -O(C_1-C_4 alkyl) or halo;

any terminal methyl moiety present in R^2 is optionally replaced with $-CH_2OH$, CF_3, $-CH_2F$, $-CH_2Cl$, $C(O)CH_3$, $C(O)CF_3$, CN, or CO_2H;

each R^6 is independently selected from hydrogen and C_1-C_6 alkyl; and

Q is selected from aryl, pyrazolyl, carbocyclyl and heterocyclyl, any of which is optionally substituted; or

R^1 and R^3 are optionally taken together with the carbon to which they are attached to form C(=O), or

R^1 and R^2 are optionally taken together to form substituted carbocyclyl, or optionally substituted heterocyclyl,

wherein:

(a) when ring A is unsubstituted phenyl, and ring B is phenyl substituted by methoxy or ethoxy, then said phenyl of ring B is not further substituted by oxazolyl;

(b) when ring A is optionally substituted phenyl or optionally substituted pyridyl and ring B is optionally substituted phenyl, then the portion of the compound represented by

-NH-C(R^1)(R^2)(R^3) is not -NH(CH_2)-aryl;

(c) when ring A is optionally substituted phenyl, and ring B is optionally substituted phenyl or pyrrolyl; then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not -NH(CH_2)C(O)NH_2;

(d) when ring A is phenyl substituted with 2 or more hydroxyl or methoxy, and ring B is optionally substituted phenyl, then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not -NH-cycloheptyl;

(e) when ring A is optionally substituted phenyl and ring B is optionally substituted phenyl, then R^1 and R^2 do not form 2,2,6,6-tetramethylpiperidin-4-yl;

(f) when ring A and ring B are optionally substituted phenyl, then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not cysteine, optionally substituted phenylalanine or leucine; or methyl ester thereof;

(g) when ring A is phenyl or pyridin-3-yl optionally substituted with one or more substituents selected from halo, methyl or CF_3, and ring B is phenyl optionally substituted with one or more substituents selected from halo, methyl or CF_3, methoxy, or CH=C(phenyl)CN, then the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is other than -NH(C_1-C_8 alkylene)-N(R^a)(R^a), -NH-1-(aminomethyl)cyclopentylmethyl, -NH-4-(aminomethyl)cyclohexylmethyl, wherein each R^a is hydrogen, C_1-C_4 alkyl or two R^as are taken together with the nitrogen to which they are commonly bound to form morpholin-4-yl or piperidin-1-yl;

(h) when ring A is phenyl, 4-chlorophenyl or 4-methylphenyl and ring B is 4-chlorophenyl or 3,4-dichlorophenyl, then the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is not -NH-isopropyl;

(i) when ring A is unsubstituted phenyl and the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is -NH-$CH_2CH_2N(CH_3)_2$, -NH-CH_2CH_2-morpholin-4-yl or -NH-CH_2CH_2OH, then ring B is other than oxadiazole, imidazole, thiazole or oxazole, each of which is substituted with -C(O)NHR^b, wherein R^b is isopropyl, cyclopropyl or 2-chloro-6-methylphenyl;

(j) when ring A is phenyl substituted with SO_2OH or SO_2Na, and ring B is phenyl, or

when ring A is phenyl substituted with SO_2OH and ring B is substituted phenyl, then the portion of the compound represented by $-NHC(R^1)(R^2)(R^3)$ is not $-NH(CH_2)_2OH$ or $-NH(CH_2)CH(OH)CH_3$; and

(k) the compound is other than:

(E)-3-(4-((4-((3-(diethylamino)propyl)amino)-6-phenyl-1,3,5-triazin-2-yl)amino)-2-methoxyphenyl)-2-phenylacrylonitrile,

4-((4-((furan-2-ylmethyl)amino)-6-(pyridin-4-yl)-1,3,5-triazin-2-yl)amino)phenol,

3-(4-((5-aminopentyl)amino)-6-((3-fluorophenyl)amino)-1,3,5-triazin-2-yl)phenol,

N^2,6-bis(3-fluorophenyl)-N^4-(piperidin-3-yl)-1,3,5-triazine-2,4-diamine,

N^2-butyl-6-phenyl-N^4-(p-tolyl)-1,3,5-triazine-2,4-diamine,

N^2-cyclohexyl-N^4,6-diphenyl-1,3,5-triazine-2,4-diamine,

(R)-3-((4-(3-chlorophenyl)-6-(pyrrolidin-3-ylamino)-1,3,5-triazin-2-yl)amino)-4-methylbenzamide,

2-chloro-4-(methylsulfonyl)-N-[4-(phenylamino)-6-(2-pyridinyl)-1,3,5,-triazin-2-yl]-benzamide,

N^2-(2-methoxyethyl)-N^4-phenyl-6-[5-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]1,3,5-triazine-2,4-diamine,

N^2-(2-furanylmethyl)-6-phenyl-N^4-[3-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine,

6-(3-methoxyphenyl)-N^2-methyl- N^4-(3-nitrophenyl)-1,3,5-triazine-2,4-diamine,

N^2-butyl- N^4-(4-methylphenyl)-6-phenyl-1,3,5-triazine-2,4-diamine, and

4-[4-(5-chloro-2-methylphenyl)-6-(methylamino)-1,3,5-triazin-2-yl]amino-benzenemethanol.

2. The compound of claim 1, wherein R^1 is independently selected from hydrogen, $-CH_3$, $-CH_2CH_3$, CH_2OH, CN, or R^1 and R^3 are taken together to form =O.

3. The compound of claim 1, wherein R^1 and R^2 are taken together to

form carbocyclyl or heterocyclyl, either of which is optionally substituted with up to 3 substituents independently selected from halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, CN, =O, -OH, and -C(O)C_1-C_4 alkyl.

4. The compound of claim 1, wherein R^2 is selected from: -(C_1-C_4 alkyl) optionally substituted with fluoro or –OH; -(C_0-C_4 alkylene)-O-(C_1-C_4 alkyl), -(C_0-C_2 alkylene)-N(R^6)-(C_1-C_6 alkyl), -(C_0-C_2 alkylene)-Q, and –O-(C_0-C_2 alkylene)-Q, wherein Q is optionally substituted with up to 3 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, =O, -C(O)- C_1-C_4 alkyl, -CN, and halo.

5. The compound of claim 4, wherein Q is selected from tetrahydrofuranyl, cyclobutyl, cyclopropyl, phenyl, pyrazolyl, morpholinyl and oxetanyl, wherein Q is optionally substituted with up to 2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, =O, fluoro, chloro, and bromo.

6. The compound of claim 1, wherein R^1 and R^2 are taken together to form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, oxetanyl, bicyclo[2.2.1]heptanyl, azetidinyl, phenyl, any of which is optionally substituted with up to 2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, C_3-C_6 cycloalkyl, -OH, -C(O)CH_3, fluoro, and chloro.

7. The compound of claim 1, wherein ring A is optionally substituted with up to two substituents independently selected from halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 hydroxyalkyl, -NH-S(O)$_2$-(C_1-C_4 alkyl), -S(O)$_2$-NH(C_1-C_4 alkyl), -CN, -S(O)$_2$-(C_1-C_4 alkyl), C_1-C_4 alkoxy, -NH(C_1-C_4 alkyl), -OH, and –NH_2.

8. The compound of claim 1, wherein ring B is selected from phenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein ring B

is optionally substituted with up to two substituents independently selected from halo, C_1-C_4 alkyl, C_2-C_4 alkynyl, C_1-C_4 haloalkyl, C_1-C_4 hydroxyalkyl, C_3-C_6 cycloalkyl, -(C_0-C_2 alkylene)-O-C_1-C_4 alkyl), -O-(C_1-C_4 alkylene)-C_3-C_6 cycloalkyl, -NH-$S(O)_2$-(C_1-C_4 alkyl), -$S(O)_2$-NH(C_1-C_4 alkyl), -$S(O)_2$-NH(C_3-C_6 cycloalkyl), -$S(O)_2$-(saturated heterocyclyl), -CN, -$S(O)_2$-(C_1-C_4 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, -OH, C(O)-O-(C_1-C_4 alkyl), saturated heterocyclyl, and –NH_2.

9. A compound having structural formula II:



(II)

or a pharmaceutically acceptable salt thereof,

wherein:

ring A' is selected from phenyl and pyridin-2-yl, wherein ring A' is optionally substituted with one or two substituents independently selected from chloro, fluoro, -CF_3, -CHF_2, -CH_3, -CH_2CH_3, -CF_2CH_3, -OH, -OCH_3, -OCH_2CH_3, -NH_2, -NH(CH_3), and -N(CH_3)$_2$;

ring B' is selected from pyridin-3-yl, pyridin-4-yl, isoxazoly-4-yl, isoxazol-3-yl, thiazol-5-yl, pyrimidin-5-yl and pyrazol-4-yl, wherein ring B' is optionally substituted with one to two substituents independently selected from halo; -CN; -OH; C_1-C_4 alkyl optionally substituted with halo, CN or -OH; -$S(O)_2$-C_1-C_4 alkyl; -S(O)-C_1-C_4 alkyl; -$S(O)_2$-NH-C_1-C_4 alkyl; -$S(O)_2$-N(C_1-C_4 alkyl)$_2$; -$S(O)_2$-azetidin-1-yl; -O-C_1-C_4 alkyl; -CH_2-O-CH_3, morpholin-4-yl, cyclopropyl, -$S(O)_2$-NH-cyclopropyl; -C(O)-O-CH_3; and

C(R^{1a})(R^{2a})(R^{3a}) is selected from C_1-C_6 alkyl optionally substituted with halo or OH; (C_0-C_1 alkylene)-cycloalkyl, wherein the alkylene is optionally substituted with methyl, and the

cycloalkyl is optionally substituted with halo, -OCH3 or methyl; and saturated heterocyclyl is optionally substituted with halo or methyl; C(O)-O-C_1-C_6 alkyl; -C(O)-(C_0-C_1 alkylene)-cyclopropyl; and C(O)-benzyl.

10. The compound of claim 9, wherein ring A' is selected from 2-chlorophenyl, 2-fluorophenyl, 2-methoxyphenyl, 3-hydroxyphenyl, 6-aminopyridin-2-yl, 6-chloropyridin-2-yl, 6-trifluoromethylpyridin-2-yl, and phenyl.

11. The compound of claim 9, wherein ring B' is selected from 2-(morpholin-4-yl)pyridin-4-yl, 2-dimethylaminopyridin-4-yl, 3-(2-methoxyethyl)phenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3-cyanomethylphenyl, 3-cyanophenyl, 3-cyclopropylaminosulfonylphenyl, 3-dimethylaminosulfonylphenyl, 3-ethylsulfonylphenyl, 3-fluorophenyl, 3-methylsulfonylphenyl, 4-fluorophenyl, 5-chloropyridin-3-yl, 5-cyanopyridin-3-yl, 5-cyanopyridin-4-yl, 5-fluoropyridin-3-yl, 5-trifluoromethylpyridin-3-yl, 6-chloropyridin-4-yl, 6-cyanopyridin-4-yl, 6-cyclopropylpyridin-4-yl, 6-ethoxypyridin-4-yl, 6-fluoropyridin-3-yl, 6-fluoropyridin-4-yl, 6-methylpyridin-4-yl, 6-trifluoromethylpyridin-4-yl, isoxazol-4-yl, phenyl, pyridine-4-yl, and thiazol-5-yl.

12. The compound of claim 9, wherein the moiety represented by $C(R^{1a})(R^{2a})(R^{3a})$ is selected from 2-hydroxycyclopentyl, 2-methylcyclopropyl, 3,3-difluorocyclobutyl, -$(CH_2)_3CH_3$, -$CH(CH_3)$- $C(CH_3)_3$, -$CH(CH_3)$-CH_2OCH_3, -C(O)-$(CH_3)_3$, -C(O)-$CH(CH_3)_2$,-C(O)-cyclopropyl, -C(O)-$OC(CH_3)_3$, -C(O)-$OCH_2CH(CH_3)_2$, -C(O)-OCH_2CH_3, -$CH(CH_3)$- $CH(CH_3)_2$, -$CH(CH_3)$-CH_2CH_3, -$CH_2C(CH3)_2$-CH_2OH, -$CH_2C(CH3)_3$, -CH_2CF_3, -$CH_2CH(CH_3)_2$, -$CH_2CH(CH_3)$-CH_2CH_3, -$CH_2CH_2CH(CH_3)_2$, -CH_2-cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl, isopropyl, oxetan-3-yl, bicycle[2.2.1]heptanyl, tetrahydropyran-4-yl, and tetrahydropyran-3-yl.

13. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

14. The composition of claim 13, further comprising a second therapeutic agent useful in the treatment of cancer.

15. Use of a compound of any one of claims 1 to 12 in the manufacture of a medicament for treating glioblastoma, glioma, myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), acute myelogenous leukemia (AML), sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, cholangiocarcinoma or angioimmunoblastic non-Hodgkin's lymphoma (NHL), each characterized by the presence of an IDH2 mutation, wherein the IDH2 mutation results in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to *R*(-)-2-hydroxyglutarate.

16. The use of claim 15, wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.

17. The use of claim 16, wherein the IDH2 mutation is an IDH2 R140Q mutation.

18. The use of claim 15, wherein the medicament further comprises a second therapeutic agent useful in the treatment of cancer.

Claims

1. A compound having Formula I or a pharmaceutically acceptable salt or hydrate thereof:



(I), wherein:

ring A is an optionally substituted ring selected from phenyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and thiazolyl;

ring B is an optionally substituted 5-6 member monocyclic aryl or monocyclic heteroaryl;

R^1 and R^3 are each independently selected from hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl, -O-C_1-C_4 alkyl, and CN, wherein any alkyl portion of R^1 is optionally substituted with -OH, NH_2, NH(C_1-C_4 alkyl), or N(C_1-C_4 alkyl)$_2$;

R^2 is selected from: -(C_1-C_6 alkyl), -(C_2-C_6 alkenyl or alkynyl), -(C_1-C_6 alkylene)-N(R^6)-(C_1-C_6 alkylene)-O-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-N(R^6)-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-N(R^6)(R^6), -(C_1-C_6 alkylene)-N(R^6)-S(O)$_{1-2}$-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-N(R^6)-S(O)$_{1-2}$-(C_0-C_6 alkyl)-Q, -(C_1-C_6 alkylene)-S(O)$_{1-2}$-N(R^6)(R^6), -(C_1-C_4 alkylene)-S(O)$_{1-2}$-N(R^6)-(C_1-C_6 alkylene)-Q, -C(O)N(R^6)-(C_1-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_1-C_6 alkyl), -C(O)N(R^6)-(C_1-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-O-C(O)-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-O-C(O)-(C_0-C_6 alkyl)-Q, -(C_1-C_6 alkylene)-O-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-O-(C_1-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-O-(C_1-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-O-C(O)-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-O-C(O)-(C_0-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-C(O)N(R^6)-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-C(O)N(R^6)-(C_0-C_6 alkylene)-Q, -(C_1-C_6 alkylene)-N(R^6)C(O)-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-N(R^6)C(O)-(C_0-C_6 alkylene)-Q, -(C_0-C_6 alkylene)-S(O)$_{0-2}$-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-S(O)$_{0-2}$-(C_0-C_6

~~alkylene)-Q, -(C_1-C_6 alkylene)-N(R^6)-C(O)-N(R^6)-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-Q,~~ -(C_0-C_6 alkylene)-C(O)-(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-C(O)-(C_0-C_6 alkylene)-Q, wherein:

any alkyl or alkylene moiety present in R^2 is optionally substituted with one or more -OH, -O(C_1-C_4 alkyl) or halo;

any terminal methyl moiety present in R^2 is optionally replaced with -CH_2OH, CF_3, -CH_2F, -CH_2Cl, C(O)CH_3, C(O)CF_3, CN, or CO_2H;

each R^6 is independently selected from hydrogen and C_1-C_6 alkyl; and

Q is selected from aryl, pyrazolyl, carbocyclyl and heterocyclyl, any of which is optionally substituted; or

R^1 and R^3 are optionally taken together with the carbon atom to which they are attached to form C(=O), or

R^1 and R^2 are optionally taken together to form substituted carbocyclyl, or optionally substituted heterocyclyl, wherein:

a. when ring A is unsubstituted phenyl, and ring B is phenyl substituted by methoxy or ethoxy; then said phenyl of ring B is not further substituted by oxazolyl;
b. when ring A is optionally substituted phenyl or optionally substituted pyridyl and ring B is optionally substituted phenyl; then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not -NH(CH_2)-aryl;
c. when ring A is optionally substituted phenyl, and ring B is optionally substituted phenyl or pyrrolyl; then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not -NH(CH_2)C(O)NH_2;
d. when ring A is phenyl substituted with 2 or more hydroxyl or methoxy, and ring B is optionally substituted phenyl; then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not -NH-cycloheptyl;
e. when ring A is optionally substituted phenyl and ring B is optionally substituted phenyl; then R^1 and R^3 do not form 2,2,6,6,-tetramethylpiperidin-4-yl;
f. when ring A and ring B are optionally substituted phenyl; then the portion of the compound represented by -NH-C(R^1)(R^2)(R^3) is not cysteine, optionally substituted phenylalanine or leucine or methyl ester thereof;

g. ~~when ring A is phenyl or pyridin-3-yl optionally substituted with one or more~~ substituents selected from halo, methyl or CF_3, and ring B is phenyl optionally substituted with one or more substituents selected from halo, methyl, CF_3, methoxy, or CH=C(phenyl)CN; then the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is other than -NH(C_1-C_8 alkylene)-N(R^a)(R^a), -NH-1-(aminomethyl)cyclopentylmethyl, -NH-4-(aminomethyl)cyclohexylmethyl, wherein each R^a is hydrogen, C_1-C_4 alkyl or two R^as are taken together with the nitrogen to which they are commonly bound to form morpholin-4-yl or pipieridin-1-yl;

h. when ring A is phenyl, 4-chlorophenyl or 4-methyl phenyl and ring B is 4-chlorophenyl or 3,4-dichlorophenyl; then the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is not -NH-isopropyl;

i. when ring A is unsubstituted phenyl and the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is -NH-$CH_2CH_2N(CH_3)_2$, -NH-CH_2CH_2-morpholin-4-yl or -NH-CH_2CH_2OH; then ring B is other than oxadiazole, imidazole, thiazole or oxazole each of which is substituted with -C(O)NHR^b, wherein R^b is isopropyl, cyclopropyl or 2-chloro-6-methylphenyl;

j. when ring A is phenyl substituted with SO_2OH or SO_2Na and ring B is phenyl, or when ring B is phenyl substituted with SO_2OH and ring B is substituted phenyl; then the portion of the compound represented by -NHC(R^1)(R^2)(R^3) is not -NH$(CH_2)_2OH$ or -NH$(CH_2)CH(OH)CH_3$; and

k. the compound is other than:

(E)-3-(4-((4-((3-(diethylamino)propyl)amino)-6-phenyl-1,3,5-triazin-2-yl)amino)-2-methoxyphenyl)-2-phenylacrylonitrile ,

4-((4-((furan-2-ylmethyl)amino)-6-(pyridin-4-yl)-1,3,5-triazin-2-yl)amino)phenol,

3-(4-((5-aminopentyl)amino)-6-((3-fluorophenyl)amino)-1,3,5-triazin-2-yl)phenol,

N^2,6-bis(3-fluorophenyl)-N^4-(piperidin-3-yl)-1,3,5-triazine-2,4-diamine,

N^2-butyl-6-phenyl-N^4-(p-tolyl)-1,3,5-triazine-2,4-diamine, N^2-cyclohexyl-N^4,6-diphenyl-1,3,5-triazine-2,4-diamine,

(R)-3-((4-(3-chlorophenyl)-6-(pyrrolidin-3-ylamino)-1,3,5-triazin-2-yl)amino)-4-methylbenzamide,

2-chloro-4-(methylsulfonyl)-N-[4-(phenylamino)-6-(2-pyridinyl)-1,3,5-triazin-2-yl]-benzamide,

N^2-(2-methoxyethyl)-N^4-phenyl-6-[5-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-1,3,5-triazine-2,4-diamine,

N^2-(2-furanylmethyl)-6-phenyl-N^4-[3-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine,

6-(3-methoxyphenyl)-N^2-methyl-N^4-(3-nitrophenyl)-1,3,5-triazine-2,4-diamine,

N^2-butyl-N^4-(4-methylphenyl)-6-phenyl-1,3,5-triazine-2,4-diamine, and

4-[[4-(5-chloro-2-methylphenyl)-6-(methylamino)]-1,3,5-triazin-2-yl]amino-benzenemethanol.

2. The compound of claim 1, wherein R^1 is independently selected from hydrogen, $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, CN, or R^1 and R^3 are taken together to form =O.

3. The compound of claim 1, wherein R^1 and R^2 are taken together to form carbocyclyl or heterocyclyl, either of which is optionally substituted with up to 3 substituents independently selected from halo. C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, -CN, =O, -OH, and -C(O)C_1-C_4 alkyl.

4. The compound of claim 1, wherein R^2 is selected from: -(C_1-C_4 alkyl) optionally substituted with fluoro or -OH; -(C_0-C_4 alkylene)-O-(C_1-C_4 alkyl), -(C_0-C_2 alkylene)-N(R^6)-(C_1-C_6 alkyl), -(C_0-C_2 alkylene)-Q, and -O-(C_0-C_2 alkylene)-Q, wherein Q is optionally substituted with up to 3 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, =O, -C(O)-C_1-C_4 alkyl, -CN, and halo.

5. The compound of claim 4, wherein Q is selected from tetrahydrofuranyl, cyclobutyl, cyclopropyl, phenyl, pyrazolyl, morpholinyl and oxetanyl, wherein Q is optionally substituted with up to 2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4

~~haloalkyl, =O, fluoro, chloro, and bromo.~~

6. The compound of claim 1, wherein R^1 and R^2 are taken together to form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, bicyclo[2.2.1]heptanyl, azetidinyl, phenyl, any of which is optionally substituted with up to 2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, C_3-C_6 cycloalkyl, -OH, -C(O)CH_3, fluoro, and chloro.

7. The compound of claim 1, wherein ring A is optionally substituted with up to two substituents independently selected from halo, -C_1-C_4 alkyl, -C_1-C_4 haloalkyl, -C_1-C_4 hydroxyalkyl, -NH-S(O)$_2$-(C_1-C_4 alkyl), -S(O)$_2$NH(C_1-C_4 alkyl), -CN, -S(O)$_2$-(C_1-C_4 alkyl), C_1-C_4 alkoxy, -NH(C_1-C_4 alkyl), -OH, -CN, and -NH_2.

8. The compound of claim 1, wherein ring B is selected from phenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein ring B is optionally substituted with up to two substituents independently selected from halo, -C_1-C_4 alkyl, -C_2-C_4 alkynyl, -C_1-C_4 haloalkyl, -C_1-C_4 hydroxyalkyl, C_3-C_6 cycloalkyl, -(C_0-C_2 alkylene)-O-C_1-C_4 alkyl, -O-(C_1-C_4 alkylene)-C_3-C_6 cycloalkyl, -NH-S(O)$_2$-(C_1-C_4 alkyl), -S(O)$_2$NH(C_1-C_4 alkyl), -S(O)$_2$-NH-(C_3-C_6 cycloalkyl), -S(O)$_2$-(saturated heterocyclyl),-CN, -S(O)$_2$-(C_1-C_4 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, -OH, C(O)-O-(C_1-C_4 alkyl), saturated heterocyclyl, and -NH_2.

9. A compound having Structural Formula II:



(II), or a pharmaceutically acceptable salt thereof, wherein:

Ring A' is selected from phenyl and pyridin-2-yl, wherein ring A' is optionally substituted with one or two substituents independently selected from chloro, fluoro, $-CF_3$, $-CHF_2$, $-CH_3$, $-CH_2CH_3$, $-CF_2CH_3$, -OH, $-OCH_3$, $-OCH_2CH_3$, $-NH_2$, $-NH(CH_3)$, and $-N(CH_3)_2$;

Ring B' is selected from pyridin-3-yl, pyridin-4-yl, isoxazoly-4-yl, isoxazol-3-yl, thiazol-5-yl, pyrimidin-5-yl and pyrazol-4-yl, wherein ring B' is optionally substituted with one to two substituents independently selected from halo; -CN; -OH; C_1-C_4 alkyl optionally substituted with halo, CN or -OH; $-S(O)_2$-C_1-C_4 alkyl; $-S(O)$-C_1-C_4 alkyl; $-S(O)_2$-NH-C_1-C_4 alkyl; $-S(O)_2$-$N(C_1$-C_4 alkyl$)_2$; $-S(O)_2$-azetidin-1-yl; -O-C_1-C_4 alkyl; $-CH_2$-O-CH_3, morpholin-4-yl, cyclopropyl, $-S(O)_2$-NH-cyclopropyl; $-C(O)$-O-CH_3; and

$-C(R^{1a})(R^{2a})(R^{3a})$ is selected from C_1-C_6 alkyl optionally substituted with halo or -OH; -(C_0-C_1 alkylene)-cycloalkyl, wherein the alkylene is optionally substituted with methyl and the cycloalkyl is optionally substituted with halo, $-OCH_3$ or methyl; saturated heterocyclyl optionally substituted with halo or methyl; $-C(O)$-O-C_1-C_6 alkyl; $-C(O)$-(C_0-C_1 alkylene)-cyclopropyl; and $C(O)$-benzyl.

10. The compound of claim 9, wherein ring A' is selected from 2-chlorophenyl, 2-fluorophenyl, 2-methoxyphenyl, 3-hydroxyphenyl, 6-aminopyridin-2-yl, 6-chloropyridin-2-yl, 6-trifluoromethylpyridin-2-yl, and phenyl.

11. The compound of claim 9, wherein ring B' is selected from 2-(morpholin-4-yl)pyridin-4-yl, 2-dimethylaminopyridin-4-yl, 3-(2-methyoxyethyl)phenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3-cyanomethylphenyl, 3-cyanophenyl, 3-cyclopropylaminosulfonylphenyl, 3-dimethylaminosulfonylphenyl, 3-ethylsulfonylphenyl, 3-fluorophenyl, 3-methylsulfonylphenyl, 4-fluorophenyl, 5-chloropyridin-3-yl, 5-cyanopyridin-3-yl, 5-cyanopyridin-3-yl, 5-cyanopyridin-4-yl, 5-fluoropyridin-3-yl, 5-trifluoromethypyridin-3-yl, 6-chloropyridin-4-yl, 6-cyanopyridin-4-yl, 6-cyclopropylpyridin-4-yl, 6-ethoxypyridin-4-yl, 6-fluoropyridin-3-yl, 6-fluoropyridin-4-yl, 6-methylpyridin-4-yl, 6-trifluoromethylpyridin-4-yl, isoxazol-4-yl, phenyl, pyridin-4-yl, and thiazol-5-yl.

~~12. The compound of claim 9, wherein the moiety represented by $C(R^{1a})(R^{2a})(R^{3a})$ is selected~~ from 2-hydroxycyclopentyl, 2-methylcyclopropyl, 3,3-difluorocyclobutyl, $-(CH_2)_3CH_3$, $-CH(CH_3)-C(CH_3)_3$, $-CH(CH_3)-CH_2OCH_3$, $-C(O)-C(CH_3)_3$, $-C(O)-CH(CH_3)_2$, -C(O)-cyclopropyl, $-C(O)-OC(CH_3)_3$, $-C(O)-OCH_2CH(CH_3)_2$, $-C(O)-OCH_2CH_3$, $-CH(CH_3)-CH(CH_3)_2$, $-CH(CH_3)-CH_2CH_3$, $-CH_2C(CH_3)_2-CH_2OH$, $CH_2C(CH_3)_3$, $-CH_2CF_3$, $-CH_2CH(CH_3)_2$, $-CH_2CH(CH_3)-CH_2CH_3$, $-CH_2CH_2CH(CH_3)_2$, $-CH_2$-cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl, isopropyl, oxetan-3-yl, bicyclo[2.2.1]heptanyl, tertrahydorpyran-4-yl, and tetrahydropyran-3-yl.

13. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

14. The composition of claim 13, further comprising a second therapeutic agent useful in the treatment of cancer.

15. Use of a composition of claim 10 in the manufacture of a medicament for treating a cancer characterized by the presence of an IDH2 mutation, wherein the IDH2 mutation results in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to *R*(-)-2-hydroxyglutarate in a patient.

16. The use of claim 15, wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.

17. The use of claim 16, wherein the IDH2 mutation is an IDH2 R140Q mutation.

18. The use of claim 15, wherein the cancer is selected from glioblastoma (or glioma), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), acute myelogenous leukemia (AML), sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, cholangiocarcinomas or angioimmunoblastic non-Hodgkin's lymphoma (NHL).

~~19. The use of claim 15, wherein the medicament further comprises a second therapeutic~~ agent useful in the treatment of cancer.